Trevi Therapeutics to Present at Key Investor and Rare Disease Forums
Event summary
- Trevi Therapeutics executives Jennifer Good (President & CEO) and James Cassella (CDO) will participate in the Leerink Partners Healthcare Conference on March 11th.
- Farrell Simon (CCO) will participate in the Access USA Rare Disease Summit on March 18th.
- Haduvio™ (oral nalbuphine ER) is Trevi's investigational therapy targeting chronic cough in IPF, non-IPF ILD, and RCC.
- The company estimates ~150,000 U.S. patients with IPF and ~228,000 with non-IPF ILD experience uncontrolled chronic cough.
The big picture
Trevi’s focus on chronic cough within IPF, non-IPF ILD, and RCC represents a strategic bet on a significant unmet need with limited existing therapeutic options. The company’s participation in these conferences underscores the importance of investor and specialist engagement in driving Haduvio’s development and potential commercialization, given the challenges inherent in rare disease drug development and the competitive landscape of respiratory therapies.
What we're watching
- Investor Sentiment
- The content of the Fireside Chat at Leerink will likely shape near-term investor perception of Haduvio’s development and commercial prospects, particularly given the competitive landscape in cough therapies.
- Rare Disease Focus
- Trevi’s participation in the Rare Disease Summit signals a deliberate effort to engage with specialists and build awareness, which will be crucial for navigating the complexities of rare disease drug launches.
- Regulatory Pathway
- The lack of scheduling by the U.S. Drug Enforcement Agency for nalbuphine provides a potential advantage, but the FDA’s eventual assessment of Haduvio’s safety and efficacy will be the ultimate determinant of its market access.
Related topics